Literature DB >> 30633076

Clinical application of echocardiographic-derived myocardial strain imaging in subclinical disease: a primer for cardiologists.

Géraldine Ong1, Andrew T Yan, Kim A Connelly.   

Abstract

PROPOSE OF REVIEW: To highlight the evidence to support the measurement of left ventricular (LV) global longitudinal strain (GLS) in the risk assessment and management of patients with valvular heart disease. RECENT
FINDINGS: Subclinical myocardial dysfunction that is characterized by impaired LV GLS is often present in patients with valvular disease. The addition of GLS to the LV systolic function assessment refines disease classification and improves both prognosis and management of valvular disease.
SUMMARY: The measurement of global systolic function is essential in risk assessment and management of all patients with valvular heart disease. Although LV ejection fraction remains the main parameter of systolic function, strain measurement has emerged as a promising systolic function marker. Strain describes deformation of the myocardium that occurs during the cardiac cycle in the longitudinal, circumferential, and radial planes. Of all the regional strain deformation measurements, evidence gathered over the last decade has shown that GLS improves detection of systolic dysfunction beyond LV ejection fraction and provides additional prognostic information.

Entities:  

Mesh:

Year:  2019        PMID: 30633076     DOI: 10.1097/HCO.0000000000000592

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  1 in total

1.  The Effects of Device-Based Cardiac Contractility Modulation Therapy on Left Ventricle Global Longitudinal Strain and Myocardial Mechano-Energetic Efficiency in Patients with Heart Failure with Reduced Ejection Fraction.

Authors:  Daniele Masarone; Michelle M Kittleson; Stefano De Vivo; Antonio D'Onofrio; Ernesto Ammendola; Gerardo Nigro; Carla Contaldi; Maria L Martucci; Vittoria Errigo; Giuseppe Pacileo
Journal:  J Clin Med       Date:  2022-10-04       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.